ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener 🦋 Butterfly 8 Analysts 🏛️ Policy 🎬 Video ★ Watchlist 🎲 Prediction Markets 📊 RQD Track Record 📅 Next Catalysts 🛡️ Overlap & Crash X-Ray 📰 Live Wire 🐋 13F Whales 🏛️ Congress & CEO Buys 🏆 $100K Arena ⌘ Pro Terminal 📐 Methodology & Corrections
Stock Ratings / Health Care / ALT
ASMB (16) AVTX (17) RZLT (38) CAPR (34) ⌘ Pro Terminal →

Altimmune Inc. (ALT) — RQD Stock Rating Cockpit

$2.04 -4.67% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $2.02

Altimmune Inc. (ALT) carries a Roarable Rating of E (Strong Sell) with 22/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (22/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →
ROARABLE E • RED ALERT Cap $416.3M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ALT Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ALT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-02, Altimmune Inc. (NASDAQ: ALT) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 22/100 at a spot price of $2.04 (-4.67% 1D, market cap $416.3M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, ALT ranks #972 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ALT compare to ASMB and AVTX in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ALT carries a Roarable E (22/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -34.7%. By comparison, ASMB (Assembly Biosciences Inc.) holds a E grade (16/100 RQD, P/E N/A, ROIC -6.5%, cap $424.7M) and AVTX (Avalo Therapeutics Inc.) posts a E grade (17/100 RQD, P/E N/A, ROIC -35.0%, cap $399.0M). Among the 5-stock peer group, ALT leads on earnings multiple (N/A) while ASMB leads on capital efficiency (-6.5% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ALT?
▼

Per ALT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001326190), Altimmune Inc. generated $41.0K in revenue (+105.0% YoY), -$88.1M in net income, and -$67.5M in free cash flow against $279.9M in total assets and $34.3M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $2.02 (-1.03%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (22/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-11.4% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510022
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk E
Cash (5)Whales (3)SEC (5)Macro (6)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-16.2% Base Target
$7 Bull$2 Base$1 Bear
📬 FREE ALT RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ALT)Realized 20D OHLCV Swing Band: ±10.4%
Deterministic 5-Pillar Attribution (22/100 Composite)
🔍 WHY ALT SCORES 22/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Macro Regime Fit+6/20 pts (27% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 34.5 (NEUTRAL RANGE)

▲ #2 Bullish Driver: Cash Engine Quality+5/20 pts (23% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
30
Grade E$2.56-12.9% Next Q
Q2 (-2Q)
27
Grade E$2.23-8.1% Next Q
Q3 (-1Q)
25
Grade E$2.05-0.5% Next Q
Current
22
Grade E$2.04-11.4% Hist 90D α
Trajectory: E (30) → E (22)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ALT Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ALT currently carries a cautious 22/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.81) and Max Pain ($2.14) forces dealer call-delta covering toward $6.76.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ALT• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “ALT Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 22%NO 78%Trade / Inspect Odds →
RSI-14 MOMENTUMNEUTRAL RANGE
34.530 Oversold · 70 Hot
ALTMAN-Z SHIELDDISTRESS RISK (<1.8)
1.30>3.0 Fortress Safe
PIOTROSKI F-SCORESOLID CORE (5–6)
5 / 99-Pt Accounting
52-WEEK LASER RANGE2% OF RANGE
L: $2$2.04H: $6
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: ERQD 5 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 6 / 40
3. Hidden Risks & Market Weather● WARNING
SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: ERQD 11 / 40
MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on ALT

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (25)

-34.7% ROIC with 42.0% gross margin and -16.23% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BEARISH (25)

Altman-Z 1.30 and Piotroski 5/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (20)

6/40 institutional & smart-money positioning score with 6/20 macro alignment.

Bull Case: Why Buyers Like ALT
  • ✓Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
  • !Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ALT)

  • ✓Walkthrough of ALT's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
ALT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -32.45%▼ SUPPORT BREAKDOWN
2026-11-02O $2.10H $2.14L $2.04C $2.04VOL 2.68M
RES: $3.68SUP: $2.80SMA50: $2.81SMA200: $3.27
$4.17$3.58$2.99$2.40$1.81RES $3.68SUP $2.80$2.042026-05-042026-06-172026-08-042026-09-172026-11-02
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ALT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ALT Butterfly Map → + Track ALT →
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth

vs. +105.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ALT today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ALT. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ALT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ALT)

Health Care Rank #972 of 1016 ⚔️ ASMB vs ALT Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ALT vs. ASMB, AVTX, RZLT, CAPR)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Altimmune Inc. (ALT) ranks #972 by composite RQD confidence (22/100, grade E) and #476 by equity capitalization ($416.3M). Within this direct 5-issuer industry benchmark cohort, ALT leads on earnings valuation at N/A trailing P/E, while ASMB leads on capital efficiency and profitability with -6.5% ROIC and — gross margin. RZLT currently holds the highest overall quantitative score in the immediate peer group at 38/100 (D-) compared with ALT at 22/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
ALT ACTIVE
Altimmune Inc.
E 22/100 — — -34.7% -4.67% $416.3M Benchmark Subject
ASMB
Assembly Biosciences Inc.
E 16/100 — — -6.5% -3.50% $424.7M /asmb-vs-alt →
AVTX
Avalo Therapeutics Inc.
E 17/100 — — -35.0% -3.63% $399.0M /avtx-vs-alt →
RZLT
Rezolute Inc. (NV)
D- 38/100 — — -35.0% -4.13% $398.5M /rzlt-vs-alt →
CAPR
Capricor Therapeutics Inc.
E 34/100 — — -35.0% -3.77% $385.5M /capr-vs-alt →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001326190

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Altimmune Inc. (ALT) reported GAAP revenue of $41.0K (+105.0% vs. FY2024 revenue of $20.0K , and -90.4% cumulative change since FY2023) , GAAP net income of -$88.1M, operating cash flow of -$67.5M, and free cash flow of -$67.5M (+15.4% YoY). On the balance sheet, ALT closed FY2025 with $279.9M in total assets against $34.3M in total debt (Altman Z-Score: 1.30, Piotroski F-Score: 5/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $41.0K -$88.1M -$67.5M -$67.5M $279.9M $34.3M
FY2024 (FY) 2024-12-31 $20.0K -$95.1M -$79.8M -$79.8M $139.3M —
FY2023 (FY) 2023-12-31 $426.0K -$88.4M -$75.8M -$75.8M — —

3. ALT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ALT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-02, Altimmune Inc. (NASDAQ: ALT) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 22/100 at a spot price of $2.04 (-4.67% 1D, market cap $416.3M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, ALT ranks #972 in composite RQD confidence.

How does ALT compare to ASMB and AVTX in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ALT carries a Roarable E (22/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -34.7%. By comparison, ASMB (Assembly Biosciences Inc.) holds a E grade (16/100 RQD, P/E N/A, ROIC -6.5%, cap $424.7M) and AVTX (Avalo Therapeutics Inc.) posts a E grade (17/100 RQD, P/E N/A, ROIC -35.0%, cap $399.0M). Among the 5-stock peer group, ALT leads on earnings multiple (N/A) while ASMB leads on capital efficiency (-6.5% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ALT?

Per ALT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001326190), Altimmune Inc. generated $41.0K in revenue (+105.0% YoY), -$88.1M in net income, and -$67.5M in free cash flow against $279.9M in total assets and $34.3M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ALT trading relative to its 50-day, 200-day, and 52-week technical levels?

ALT last traded at $2.04 (-4.67% on volume of 3,519,884 shares), positioning the stock -27.40% below its 50-day simple moving average ($2.81) and -37.61% below its 200-day simple moving average ($3.27). Across its 52-week range of $1.99 to $6.44, ALT sits at the 1.1% percentile with a 14-day RSI of 34.5 (NEUTRAL RANGE) and an implied next-earnings move of ±10.4% ($1.83 to $2.25).

ALT Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell ALT stock right now?

Altimmune Inc. (ALT) currently earns a Roarable Rating of E (Strong Sell — SELL) with 22/100 RQD Confidence. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

What is ALT's 12-month price target and RQD AI Jury consensus?

ALT's 12-month base price target is $1.71 (range $1.33 to $6.76), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: ALT RQD Cockpit ALT 12M Forecast ALT Earnings & Move ALT Dividends & DRIP ALT Insiders & 13F ALT Whale Options ALT Profit Sankey ALT News & Why
ROARABLE RATING BRIEF • RQD 22/100 (E) ✓ STAGE-C NUMBER FIREWALL VERIFIED

ALT — Altimmune Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:36:48Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, ALT carries an RQD Score of 22 with a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are:

  • Fundamental Cash Engine: 5 / 20. Per the RQD rating, ROIC is -34.7% and FCF yield is -16.23%. For an investor, this means the business is currently consuming capital rather than generating it, so valuation cannot be anchored to cash earnings.
  • Whale / 13F Flow: 3 / 20. Per the RQD rating, this pillar reflects institutional accumulation and options positioning. The score is weak, signaling limited evidence of sustained large-holder conviction in the source data.
  • Insider Conviction: 3 / 20. Per the RQD rating, this pillar reflects SEC Form 4 and Congressional PTR cluster flow. The low score indicates insider activity does not provide a supportive signal.
  • Macro Regime Fit: 6 / 20. Per the RQD rating, beta is 1.0 with a sector sensitivity assessment. The score suggests the stock does not offer a favorable macro-regime fit in the rating's framework.
  • Forensic Balance Sheet: 5 / 20. Per the RQD rating, Altman Z is 1.3, Piotroski F is 5/9, and Debt/Equity is 0.15. The Altman figure sits in a distress-oriented range, so balance sheet resilience is a material concern despite low leverage.

Taken together, the pillars point to a high-risk profile: weak cash generation, limited institutional and insider support, and a distressed-leaning Altman score. Upside drivers would need to come from a shift in cash-flow trajectory or external catalysts, neither of which is established in the source data. Valuation tradeoffs are unresolved because P/E and EV/EBITDA are unavailable.

Business

Altimmune Inc. (ALT) is a NASDAQ-listed issuer in the Health Care sector, operating in Biotechnology: Pharmaceutical Preparations, per the profile. Per the profile, the company carries a market capitalization of $0.4B. Per the SEC financials, reported revenue was $0.0M in FY 2025 and FY 2024 and $0.4M in FY 2023. Not available in source data: product lines, customer base, and revenue model detail.

Financial Trend

PeriodRevenueOperating IncomeNet IncomeEPSFCFCashDebt
FY 2025$0.0M$-94.5M$-88.1MN/A$-67.5M$43.8M$34.3M
FY 2024$0.0M$-103.2M$-95.1MN/A$-79.8M$36.9MN/A
FY 2023$0.4M$-95.9M$-88.4MN/A$-75.8MN/AN/A

Per the market data, gross margin is 0%, operating margin is -60%, and net margin is -60%. Per the RQD rating, ROIC is -34.7%. Per the RQD rating, the Altman Z-Score is 1.3 and the Piotroski F-Score is 5/9, with Debt/Equity at 0.15. The reported losses and negative free cash flow across all three periods indicate sustained cash consumption.

Recent Catalysts & News Wire Analysis

Per the recent news feed (all items tagged YELLOW, MARKET WIRE):

  • Pemvidutide data presentation: A headline states Altimmune will present new data on pemvidutide in serious liver diseases at AASLD The Liver Meeting 2026. This is the most substantive pipeline catalyst referenced.
  • CFO share surrender: A report states the CFO surrendered 4,379 shares solely to cover stock-vesting taxes. This is a routine tax-withholding event and not a discretionary insider sale.
  • Options and ownership coverage: Moomoo options chain and MarketBeat institutional ownership items were referenced without specific holdings detail.
  • Analyst forecast coverage: A Simply Wall St forecast headline was referenced without figures.
  • Insider selling alert: A headline references a pullback from $2.43 resistance on 2026-10-14 alongside insider selling alerts. The source does not provide transaction detail.

Risk watch items: the sustained losses, negative FCF, and Altman distress-range score. Per the Butterfly Supply-Chain Graph, no proprietary signals are present.

Open Questions

  • What is the pemvidutide clinical and regulatory timeline, and what does the AASLD data presentation show?
  • What is the cash runway given FY 2025 cash of $43.8M against FCF of $-67.5M?
  • Why are P/E, forward P/E, EV/EBITDA, and EPS unavailable, and what would they show?
  • What drove the FY 2025 debt of $34.3M, and what are its terms and maturities?
  • What were the specific insider selling transactions referenced in the October 2026 alert?

ALT Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Altimmune Inc. (ALT) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ALT Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ALT Bull vs. Bear Conversation Board — What's Your Call at $2.04?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ALT 🐻 67% BEARISH CONVICTION
1. Pick Your Side on ALT:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $1.88 (-12.1%)
📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is ALT (E • RQD 22/100) a Buy at $2.14?

Welcome to the ALT (Altimmune Inc.) Roar Pit. Current RQD Composite is 22/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

RE RedlineAuditor Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $1.63 (-23.8%)
Spot @ $2.14

Pump the brakes on ALT — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on ALT, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Altimmune Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

CA CashFlowKing Verified K Arena Trader 🐂 BULLISH 🎯 Target: $2.61 (+22.0%)
Spot @ $2.14

ALT cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on ALT, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $2.14 (52-wk range $1.99 - $6.44), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $755.72 -0.38% QQQ $690.49 -1.44% DIA $517.13 -0.37% IWM $279.33 +0.96% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.36 -0.94% GLD $355.78 -1.34%